Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07778498 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07778498 · ClinicalTrials.gov record · last posted 2026-08-21

A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

StatusNot Yet Recruiting
PhasePhase 1/2
Started2026-09-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors. The main objectives of this study are : • To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ102 • to show preliminary antitumor activity in patients with advanced ovarian or other solid tumors. Participants will: • Receive intravenous (IV) infusions of TJ102 at escalating dose levels (during dose escalation) or at the selected expansion dose. • Undergo regular tumor imaging to assess response. • Provide blood samples for pharmacokinetics (PK) and biomarker analysis. • Be monitored for side effects and overall tolerability. This study is being conducted in adult patients with advanced or metastatic ovarian or other solid tumors who have exhausted standard treatment options.
Trial Details
NCT Number NCT07778498
Lead Sponsor Phrontline Biopharma
Conditions Ovarian Cancer
Enrollment 150 participants
Start Date 2026-09-15
Primary Completion 2029-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-21